Preliminary Results of a Phase 1 Study in Healthy Subjects Administered Inclacumab, a Fully Human IgG4 Anti-P-Selectin Monoclonal Antibody in Development for Treatment of Sickle Cell Disease

Authors
Category Primary study
JournalBlood
Year 2021
This article has no abstract
Epistemonikos ID: 5cda7fbf170f0cab561ac78b10ac632f22c6577d
First added on: Feb 13, 2025